Loading clinical trials...
Loading clinical trials...
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT04944940 · Spinal and Bulbar Muscular Atrophy, Kennedys Disease, and more
NCT03555578 · Spinal and Bulbar Muscular Atrophy
NCT06169046 · Spinal and Bulbar Muscular Atrophy
NCT02156141 · Spinal and Bulbar Muscular Atrophy, Healthy Subjects
NCT00303446 · Kennedy's Disease, Spinal and Bulbar Muscular Atrophy
Novartis Investigative Site
Orange, California
National Institutes of Health
Bethesda, Maryland
Novartis Investigative Site
Columbus, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions